Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease
Overview
Authors
Affiliations
Background And Aims: It is proposed that impaired expansion of subcutaneous adipose tissue (SAT) and an increase in adipose tissue (AT) fibrosis causes ectopic lipid accumulation, insulin resistance (IR), and metabolically unhealthy obesity. We therefore evaluated whether a decrease in SAT expandability, assessed by measuring SAT lipogenesis (triglyceride [TG] production), and an increase in SAT fibrogenesis (collagen production) are associated with NAFLD and IR in persons with obesity.
Approach And Results: In vivo abdominal SAT lipogenesis and fibrogenesis, expression of SAT genes involved in extracellular matrix (ECM) formation, and insulin sensitivity were assessed in three groups of participants stratified by adiposity and intrahepatic TG (IHTG) content: (1) healthy lean with normal IHTG content (Lean-NL; n = 12); (2) obese with normal IHTG content and normal glucose tolerance (Ob-NL; n = 25); and (3) obese with NAFLD and abnormal glucose metabolism (Ob-NAFLD; n = 25). Abdominal SAT TG synthesis rates were greater (P < 0.05) in both the Ob-NL (65.9 ± 4.6 g/wk) and Ob-NAFLD groups (71.1 ± 6.7 g/wk) than the Lean-NL group (16.2 ± 2.8 g/wk) without a difference between the Ob-NL and Ob-NAFLD groups. Abdominal SAT collagen synthesis rate and the composite expression of genes encoding collagens progressively increased from the Lean-NL to the Ob-NL to the Ob-NAFLD groups and were greater in the Ob-NAFLD than the Ob-NL group (P < 0.05). Composite expression of collagen genes was inversely correlated with both hepatic and whole-body insulin sensitivity (P < 0.001).
Conclusions: AT expandability is not impaired in persons with obesity and NAFLD. However, SAT fibrogenesis is greater in persons with obesity and NAFLD than in those with obesity and normal IHTG content, and is inversely correlated with both hepatic and whole-body insulin sensitivity.
Understanding Adipose Tissue Dysfunction.
Bluher M J Obes Metab Syndr. 2024; 33(4):275-288.
PMID: 39734091 PMC: 11704217. DOI: 10.7570/jomes24013.
Adipose Tissue Hypoxia in Obesity: Clinical Reappraisal of Hypoxia Hypothesis.
Engin A Adv Exp Med Biol. 2024; 1460:329-356.
PMID: 39287857 DOI: 10.1007/978-3-031-63657-8_11.
PAQR4 regulates adipocyte function and systemic metabolic health by mediating ceramide levels.
Zhu Q, Chen S, Funcke J, Straub L, Lin Q, Zhao S Nat Metab. 2024; 6(7):1347-1366.
PMID: 38961186 PMC: 11891014. DOI: 10.1038/s42255-024-01078-9.
MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight.
Pan Z, Khatry M, Yu M, Choudhury A, Sebastiani G, Alqahtani S Ther Adv Endocrinol Metab. 2024; 15:20420188241252543.
PMID: 38808010 PMC: 11131400. DOI: 10.1177/20420188241252543.
Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity.
Petersen M, Smith G, Palacios H, Farabi S, Yoshino M, Yoshino J Cell Metab. 2024; 36(4):745-761.e5.
PMID: 38569471 PMC: 11025492. DOI: 10.1016/j.cmet.2024.03.002.